Journals / Turkish Journal of Gastroenterology / 2019 / Cilt: 30 - Sayı: 5

Serum miR-551b-3p is a potential diagnostic biomarker for gastric cancer

Pages
415–419
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The kappa consistency test had a kappa value of 0.667 (p=0.000)in GC.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/Aims: Gastric cancer (GC) is one of the most common gastrointestinal malignancies.
📊
Key Findings & Data:Many studies have demonstratedthat serum microRNAs have potential applications as non-invasive biomarkers for cancer diagnosis.
💡
Conclusion & Impact:The kappa consistency test had a kappa value of 0.667 (p=0.000)in GC.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Background/Aims: Gastric cancer (GC) is one of the most common gastrointestinal malignancies. Many studies have demonstratedthat serum microRNAs have potential applications as non-invasive biomarkers for cancer diagnosis. The aim of the present study wasto investigate the expression of serum miR-551b-3p in patients with GC and to explore its potential as a diagnostic biomarker in GC.Materials and Methods: The expression of miR-551b-3p was detected using quantitative reverse transcription polymerase chain reaction in preoperative serum samples of 50 patients with GC and 53 healthy individuals. An analysis was performed to determine thecorrelation between serum miR-551b-3p levels and clinicopathological characteristics of patients with GC. The receiver operating characteristic curve was generated, and the cut-off point of serum miR-551b-3p for the diagnosis of GC was selected. The clinical value ofserum miR-551b-3p for GC was analyzed by a consistency test.Results: The expression of serum miR-551b-3p was significantly lower in patients with GC than in healthy individuals (p=0.000). Lowlevel was positively associated with tumor size (p=0.014), depth of invasion (p=0.001), and Tumor-Node-Metastasis stage (p=0.022).The area under the curve for serum miR-551b-3p distinguishing patients with GC from healthy individuals was 0.860 (95% CI: 0.787-0.933, p=0.000), with a specificity of 96.2% and a sensitivity of 70%. The kappa consistency test had a kappa value of 0.667 (p=0.000)in GC.

🔖

Cite This Article

BAI, S. Y., JI, R., WEI, H., GUO, Q. H., YUAN, H., CHEN, Z. F., WANG, Y. P., LIU, Z., YANG, X. Y., ZHOU, Y. N. (2019). Serum miR-551b-3p is a potential diagnostic biomarker for gastric cancer. Turkish Journal of Gastroenterology, Cilt: 30 - Sayı: 5, 415–419. https://ajindex.com/articles/409247

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016
  2. [CrossRef] 2. Mitchell P, Parkin R, Kroh E, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008
  3. 10513-8. [CrossRef] 3. Cho W. Circulating MicroRNAs as Minimally Invasive Biomarkers for Cancer Theragnosis and Prognosis. Front Genet 2011
  4. [CrossRef] 4. Chen Z, Liu X, Liu M, et al. [Expression of miR-551b-3p in gastric cancer cell lines and tissues and its clinical significance]. Zhonghua Zhong Liu Za Zhi 2014
  5. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008
  6. [CrossRef] 6. Brase J, Wuttig D, Kuner R, Sültmann H. Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer 2010
  7. [CrossRef] 7. Wittmann J, Jäck H. Serum microRNAs as powerful cancer biomarkers. Biochim Biophys Acta 2010
  8. [CrossRef] 8. Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 2010
  9. [CrossRef] 9. Zhang H, Yang L, Zhu Y, et al. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 2011
  10. [CrossRef] 10. Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano A, Hoon D. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem 2011
  11. [CrossRef] 11. Wang J, Huang S, Zhao M, et al. Identification of a circulating microRNA signature for colorectal cancer detection. PLoS ONE 2014
  12. e87451. [CrossRef] 12. Sierzega M, Kaczor M, Kolodziejczyk P, Kulig J, Sanak M, Richter P. Evaluation of serum microRNA biomarkers for gastric cancer based on blood and tissue pools profiling: the importance of miR-21 and miR-331. Br J Cancer 2017
  13. [CrossRef] 13. Chen X, Hu Z, Wang W, et al. Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int J Cancer 2012
  14. [CrossRef] 14. Heegaard N, Schetter A, Welsh J, Yoneda M, Bowman E, Harris C. Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer 2012
  15. [CrossRef] 15. Foss